Literature DB >> 33962210

Acute necrotizing encephalopathy-linked mutations in Nup358 impair interaction of Nup358 with TNRC6/GW182 and miRNA function.

Prachi Deshmukh1, Aditi Singh1, Deepak Khuperkar1, Jomon Joseph2.   

Abstract

MicroRNA (miRNA)-mediated translational suppression of mRNAs is involved in the regulation of multiple cellular processes. A recent study showed that Nup358, a protein mutated in a neurological disorder called acute necrotizing encephalopathy 1 (ANE1), helps in the coupling of miRNA-induced silencing complex (miRISC) - consisting of miRNA, AGO and GW182/TNRC6 proteins - with the target mRNA. Here we provide a detailed characterization of the interaction between Nup358 and GW182. We identified that the N-terminal region of Nup358 directly interacts with the C-terminal silencing domain of GW182. Interestingly, ANE1-associated Nup358 mutants display reduced interaction with GW182. Consistent with this, one of the prevalent ANE1 mutations, 585th threonine (T) residue changed to methionine (M) [T585M] compromised Nup358's ability to function in the miRNA pathway. Collectively, these results suggest that the ANE1-associated mutations in Nup358 might affect the miRNA pathway and contribute to the development of ANE1.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ANE1; CNOT complex; Nucleoporin; Phase-separation; Translation; miRNA

Year:  2021        PMID: 33962210     DOI: 10.1016/j.bbrc.2021.04.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

Review 1.  Roles of Nucleoporin RanBP2/Nup358 in Acute Necrotizing Encephalopathy Type 1 (ANE1) and Viral Infection.

Authors:  Jing Jiang; Yifan E Wang; Alexander F Palazzo; Qingtang Shen
Journal:  Int J Mol Sci       Date:  2022-03-24       Impact factor: 5.923

2.  Workshop on RanBP2/Nup358 and acute necrotizing encephalopathy.

Authors:  Alexander F Palazzo; Jomon Joseph; Ming Lim; Kiran T Thakur
Journal:  Nucleus       Date:  2022-12       Impact factor: 4.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.